Table 2A. Pooled Gram-negative antibiogram (n/N, n(%)).
|
Susceptible isolates/total isolates (%)
|
||||||
| Antibiotic (year) | E. cloacae | E. coli | K. pneumoniae |
Other
Enterobacterales |
A. baumannii | P. aeruginosa |
| Ampicillin | ||||||
| 2015 | 1/39 (2.6) | 4/30 (13.3) | - | 13/44 (29.6) | - | - |
| 2017 | 1/33 (3.0) | 4/39 (10.3) | - | 14/57 (24.6) | - | - |
| Amoxicillin-clavulanate | ||||||
| 2015 | 1/38 (2.6) | 19/30 (63.3) | 34/85 (40.0) | 27/50 (54) | - | - |
| 2017 | 0/43 (0.0) | 19/39 (48.7) | 30/77 (39.0) | 23/60 (38.3) | - | - |
| Piperacillin-tazobactam | ||||||
| 2015 | 27/39 (69.2) | 20/30 (66.7) | 60/84 (71.4) | 44/50 (88.0) | 6/79 (7.6) | 38/46 |
| 2017 | 22/26 (84.6) | 25/33 (75.8) | 36/57 (63.1) | 41/48 (85.4) | 16/49 (32.7) | (82.6) 24/27 |
| Cefoxitin | ||||||
| 2015 | 0/39 (0.0) | 24/30 (80.0) | 85/85 (100.0) | 31/55 (56.4) | - | - |
| 2017 | 0/29 (0) | 27/33 (81.8) | 47/54 (87.0)† | 20/50 (80.0) | - | - |
| Ceftriaxone | ||||||
| 2015 | 26/37 (70.3) | 18/30 (60.0) | 37/84 (44.0) | 51/55 (92.7) | - | - |
| 2017 | 23/29 (79.3) | 22/33 (66.7) | 34/56 (60.7) | 33/52 (63.5)* | - | - |
| Ceftazidime | ||||||
| 2015 | 30/39 (76.9) | 19/30 (63.3) | 41/85 (48.2) | 50/55 (90.0) | 7/80 (8.8) | 41/52 (78.9) |
| 2017 | 25/30 (83.3) | 24/34 (70.6) | 35/57 (61.4)§ | 39/51 (76.5) | 21/51 (41.2)‡ | 24/27 (88.9) |
| Cefepime | ||||||
| 2015 | 30/39 (76.9) | 20/30 (66.7) | 42/85 (49.4) | 52/55 (94.6) | 6/80 (7.5) | 38/52 (73.1) |
| 2017 | 25/30 (83.3) | 25/32 (78.1) | 34/56 (60.7) | 37/48 (77.1)* | 19/51 (37.3)‡ | 24/27 (88.9) |
| Ertapenem | ||||||
| 2015 | 39/39 (100) | 30/30 (100) | 85/85 (100) | 55/55 (100) | - | - |
| 2017 | 27/27 (100) | 33/33 (100) | 47/52 (90.4) | 48/48 (100) | - | - |
| Imipenem | ||||||
| 2015 | 39/39 (100) | 30/30 (100) | 85/85(100) | 37/37 (100) | 6/80 (7.5) | 37/52 (71.2) |
| 2017 | 29/29 (100) | 33/33 (100) | 56/56 (100) | 46/46 (100) | 17/49 (34.7)§ | 24/27 (88.9) |
| Meropenem | ||||||
| 2015 | 39/39 (100) | 30/30 (100) | 85/85 (100) | 55/55 (100) | 6/80 (7.5) | 39/52 (75.0) |
| 2017 | 31/31 (100) | 34/34 (100) | 59/59 (100) | 49/49 (100) | 20/51 (39.2)‡ | 25/28 (89.3) |
| Ciprofloxacin | ||||||
| 2015 | 38/39 (97.4) | 22/29 (75.9) | 76/85 (89.4) | 54/55 (98.2) | 33/79 (41.8) | 46/52 (88.5) |
| 2017 | 22/27 (81.5) | 19/22 (86.4) | 35/45 (77.8) | 26/30 (86.7) | 39/53 (73.6)§ | 27/29 (93.1) |
| Gentamicin | ||||||
| 2015 | 28/38 (73.7) | 28/30 (93.3) | 41/85 (48.2) | 52/55 (94.6) | 25/79 (31.6) | 45/52 (86.5) |
| 2017 | 30/36 (83.3) | 27/36 (75.0) | 33/65 (50.8) | 47/51 (92.2) | 33/55 (60.0)* | 24/29 (82.8) |
| Amikacin | ||||||
| 2015 | 34/39 (87.2) | 30/30 (100) | 79/84 (94.1) | 52/52 (100) | 13/24 (54.2) | 46/51 (90.2) |
| 2017 | 41/43 (95.4) | 38/38 (100) | 67/77 (87.0) | 60/60 (100.0) | 34/50 (68) | 39/41 (95.1) |
|
| ||||||
| Resistance profile | % Isolates | |||||
|
| ||||||
| Amp C | ||||||
| 2015 | 100 | 20 | 0 | 43.6 | - | - |
| 2017 | 100 | 18.2 | 13.0§ | 20.0§ | - | - |
| ESBL | ||||||
| 2015 | 23.1 | 40 | 56 | 10.3 | - | - |
| 2017 | 16.7 | 33.3 | 35.4* | 36.5‡ | - | - |
| CRE | ||||||
| 2015 | 0 | 0 | 0 | 0 | - | - |
| 2017 | 0 | 0 | 6.49* | 0 | - | - |
| MDR | ||||||
| 2015 | - | - | - | - | 92.5 | 67.31 |
| 2017 | - | - | - | - | 63.64‡ | 6.89‡ |
E. cloacae = Enterobacter cloacae
E. coli = Escherichia coli
K. pneumoniae = Klebsiella pneumoniae
AmpC = AmpC beta-lactamases
ESBL = extended spectrum β-lactamase
CRE = carbapenem-resistant Enterobacterales
MDR = multidrug-resistant
- = not applicable
* p≤0.05
† p≤0.001
‡ p≤0.0001
‡ p≤0.0005